Rankings
▼
Calendar
CTMX Q3 2021 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$822M
Q3 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$18M
-1.1% YoY
Gross Profit
$18M
100.0% margin
Operating Income
-$23M
-128.7% margin
Net Income
-$23M
-128.4% margin
EPS (Diluted)
$-0.35
QoQ Revenue Growth
+8.0%
Cash Flow
Operating Cash Flow
-$30M
Free Cash Flow
-$30M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$371M
Total Liabilities
$260M
Stockholders' Equity
$112M
Cash & Equivalents
$236M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$18M
$18M
-1.1%
Gross Profit
$18M
$18M
-1.1%
Operating Income
-$23M
-$15M
-52.0%
Net Income
-$23M
-$15M
-53.5%
← FY 2021
All Quarters
Q4 2021 →